Lenvatinib Mesylate + Paclitaxel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Carcinoma
Conditions
Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer
Trial Timeline
May 27, 2016 → Mar 31, 2022
NCT ID
NCT02788708About Lenvatinib Mesylate + Paclitaxel
Lenvatinib Mesylate + Paclitaxel is a phase 1 stage product being developed by Eisai for Fallopian Tube Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02788708. Target conditions include Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02788708 | Phase 1 | Completed |
Competing Products
20 competing products in Fallopian Tube Carcinoma